Texas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday.
Texas holds off on proposed limits for costly hepatitis drug
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.